Читать книгу Anti-Aging Therapeutics Volume XV - A4M American Academy - Страница 25

Agarwal PK et al. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb; 173(2):533-6.

Alexander GM, Swerdloff RS, Wang C, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Hormones and Behavior 1998; 33(2):85-94.

Algarte-Genin M et al. Prevention of Prostate Cancer by Androgens: Experimental paradox or clinical reality? European Urology 46 (Sept 2004) 285-295

Araujo Ab et al Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clinical Endocrinol Metabolism 2004 Dec; 89(12):5920-6.

Arnlov J et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1; 145(3):176-84

Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, Uzun O, Bolu E, Saglam K. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012 Aug 31.

Barrett-Connor E et al. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999 Oct; 84(10):3681-5

Basaria et al. November 2001 Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases. The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 11 5108-5117

Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun; 91(6):1995-2010.

Bhasin S. et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997 Feb; 82(2):407-13.

Bhasin S. The dose-dependent effects of testosterone on sexual function and on muscle mass and function. Mayo Clin Proc. 2000 Jan; 75 Suppl: S70-5

Boyanov MA et al. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 Mar;6(1):1-7.

Burris A et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992 Jul-Aug;13(4):297-304

Caminiti G et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009 Sep 1;54(10):919-27

Caretta N et al. Erectile dysfunction in aging men: testosterone role in therapeutic protocols. J Endocrinol Invest. 2005; 28 (11 Suppl Proceedings):108-11

Cassidenti D et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro Obstetrics & Gynecology 1991; 78:103-107

Channer KS, Jones TH Cardiovascular effects of testosterone: implications of the "male menopause"? Heart. 2003 Feb; 89(2):121-2.

Chen C et al. Cancer Epidemiol Biomarkers Prev. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. 2003 Dec; 12(12):1410-6.

Cooper CS et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 1998 Feb; 159(2):441-3

Daniell HW et al. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002 Oct; 3(5):377-84.

Dimitrakakis C et al. Breast cancer incidence in women using testosterone in addition to usual hormone therapy. Menopause 11 (5) 2004

Edinger KL et al. Testosterone's anti-anxiety and analgesic effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Psychoneuroendocrinology. 2005 Jun; 30(5):418-30

El-Sakka AI et al. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005 Mar; 2(2):235-40,

Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies Endogenous Hormones and Prostate Cancer Collaborative Group. J Natl Cancer Inst 2008 100: 170-183

English KM et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000 Oct 17; 102(16):1906-11

Fink B et al. The 2nd-4th digit ratio (2D:4D) and neck circumference: implications for risk factors in coronary heart disease. Int J Obes (Lond). 2006 Apr; 30(4):711-4

Foresta C et al. Reduced Number of Circulating Endothelial Progenitor Cells in Hypogonadal Men. Journal of Clinical Endocrinology & Metabolism 91(11):4599–4602

Fukui, M et al. Diabetes Care 26:1869–1873, June, 2003

Gould DC, Kirby RS Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?Prostate Cancer Prostatic Dis. 2006;9(1):14-8

Gouras GK et al. Proc Natl Acad Sci U S A 2000 Feb 1; 97(3):1202-5

Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-1025.

Gunawardena, K et al. Testosterone is a potential augmentor of antioxidant induced apoptosis in human prostate cancer cells. Cancer Detect Prev. 2002; 26(2):105-13

Habib FK, et al. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. 2005 Mar 20; 114(2):190-4.

Hak, Elisabeth et al. Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men: The Rotterdam Study. The Journal of Clinical Endocrinology & Metabolism Vol. 87, 2002, No. 8 3632-3639

Hatzoglou A. et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. (Journal of Clinical Endocrinology & Metabolism 2004, 10.1210/jc.2004-0801)

Hau M et al. Testosterone reduces responsiveness to nociceptive stimuli in a wild bird. Horm Behav. 2004 Aug; 46(2):165-70.

Hoffman MA. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000 Mar; 163(3):824-7

Hogervorst E et al. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol. 2004 Nov-Dec; 39(11-12):1633-9.

Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69:322-337.

Iczkowski, K. et al. The Dual 5 alpha reductase inhibitor dutasteride induces atrophic changes and decreases cancer volume in the human prostate. Urology 65:76-82, 2005

Jankowska EA. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13; 301(18):1892-901.

Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006 Feb;10(2):77-82.

Jeong, HJ et al. Inhibition of aromatase activity by flavinoids. ArchPharm Res. 1999 Jun; 22(3):309-12

Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828-837.

Daniel M Kelly and T Hugh Jones. “Testosterone: a vascular hormone in health and disease,” J Endocrology 217:3 R47–R71.

Keogh E Can a sexually dimorphic index of prenatal hormonal exposure be used to examine cold pressor pain perception in men and women? : Eur J Pain. 2006 Apr 4

Khaw KT, Barrett-Connor EJ. Blood pressure and endogenous testosterone in men: an inverse relationship. Hypertens. 1988 Apr; 6(4):329-32.

Khaw KT. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. Circulation. 2007; 116:2694-2701

Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;8:3204-3213.

Korbonits M, Slawik M A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males J Clin Endocrinol Metab. 2004 May; 89(5):2039-43

Korenman SG, Morley JE, Mooradian AD, et al. 1990 Secondary hypogonadism in older men: its relationship to impotence. J Clin Endocrinol Metab. 71:963–969.

Ekaterina L. Kovacheva, Amiya P. Sinha Hikim, Ruoqing Shen, Indranil Sinha, Indrani Sinha-Hikim. “ Testosterone Supplementation Reverses Sarcopenia

in Aging through Regulation of Myostatin, c-Jun NH2-Terminal Kinase, Notch, and Akt Signaling Pathways.” Endocrinology, Feb. 2010; 151(2):628–638.

Kupelian V et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006 Mar; 91(3):843-50.

Laaksonen DE et al. Sex hormones, inflammation and the metabolic syndrome: a population-albased study.Eur J Endocrinol. 2003 Dec; 149(6):601-8

Laaksonen DE et al. Testosterone and Sex Hormone-Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men.Diabetes Care. 2004 May;27(5):1036-1041

LeBlanc ES, Wang PY, Janowsky JS, Neiss MB, Fink HA, Yaffe K, Marshall LM, Lapidus JA, Stefanick ML, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Research Group. Association between sex steroids and cognition in elderly men. Clin Endocrinol (Oxf). 2010 Mar;72(3):393-403.

LeBlanc ES, Wang PY, Lee CG, et al. Higher testosterone levels are associated with less loss of lean body mass in older men. J Clin Endocrinol Metab. 2011;96:3855-3863.

Leder BZ et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.J Clin Endocrinol Metab. 2004 Mar; 89(3):1174-80.

Lunenfeld B Endocrinology of the aging male. Minerva Ginecol. 2006 Apr; 58(2):153-70

Maggio M et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor (sIL-6r) in older men.J Clin Endocrinol Metab. 2005 Nov 1

Makinen J et al. Increased carotid atherosclerosis in andropausal middle-aged men.J Am Coll Cardiol. 2005 May 17; 45(10)

Malkin CJ et al. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003 Sep; 178(3):373-80

Malkin CJ et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug; 90(8):871-6.

Malkin CJ et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2005 Aug 10

Malkin CJ et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men J Clin Endocrinol Metab. 2004 Jul; 89(7):3313-8.

Marks LS et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA. 2006 Nov 15; 296(19):2369-71.

Moffat SD, Resnick SM. Long-term measures of free testosterone predict regional cerebral blood flow patterns in elderly men.Neurobiol Aging. 2006 May 11

Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety.J Endocrinol Invest. 2005; 28(3 Suppl):122-7

Morales A.Androgen replacement therapy and prostate safety.Eur Urol 2002 Feb; 41(2):113-20

Morgentaler A et al. Testosterone therapy in men with untreated prostate cancer. Journal of Urology 2011 Apr;185(4)9.

Morgentaler A Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. Eur Urol. 2006 Jul 26

Morgentaler A Testosterone replacement therapy and prostate risks: where's the beef? Can J Urol. 2006 Feb; 13 Suppl 1:40-3.

Morgentaler A. et al Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009 Feb; 6(2):574-7.

Morgentaler, M. Guideline for Male Testosterone therapy. A clinician’s perspective. J. Clin Endo Metab. 92 (2) 416-417, 2007 no abstract available

Morley J. Testosterone and frailty. Clin Geriatr Med 1997 Nov;13(4):685-95

Morley JE. Testosterone replacement and the physiologic aspects of aging in men.Mayo Clin Proc. 2000 Jan; 75 Suppl: S83-7

Mudali S, Dobs AS Effects of testosterone on body composition of the aging male. Mech Ageing Dev. 2004 Apr; 125(4):297-304

Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. Mech Ageing Dev. 2004;125:297-304.

Muller M et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004 May 4; 109(17):2074-9.

Muniyappa R et al. Long-Term Testosterone Supplementation Augments Overnight Growth Hormone Secretion in Healthy Older Men. Am J Physiol Endocrinol Metab. 2007

Vakkat Muraleedharan and T. Hugh Jones. “Review: Testosterone and the metabolic syndrome,” Therapeutic Advances in Endocrinology and Metabolism 2010 1: 207.

Nathan L et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3589-93

Nettleship JE, Jones RD, Channer KS, Jones TH. Testosterone and coronary artery disease. Front Horm Res. 2009;37:91-107.

O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav. 2002;75:557-566.

Oettel M et al. Progesterone: the forgotten hormone in men? Aging Male. 2004 Sep; 7(3):236-57

Padero MC et al. Androgen supplementation in older women: too much hype, not enough data. J Am Geriatr Soc 2002 Jun; 50(6):1131-40

Pantuck AJ et al. Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer.Clin Cancer Res. 2006 Jul 1;12(13):4018-4026

Phillips GB Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997 Apr; 17(4):695-701

Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab. 2005 May;90(5):2708-11

Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999 Sep 1; 59(17):4161-4

Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004 Apr;90(4):446-7.

Rao et al. Effect of testosterone on threshold of pain.Indian J Physiol Pharmacol. 1981 Oct-Dec; 25(4):387-8.

Rhoden EL, Averbeck MA. [Prostate carcinoma and testosterone: risks and controversies]. Arq Bras Endocrinol Metabol. 2009 Nov;53(8):956-62.

Rosano GM et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999 Apr 6; 99(13):1666-70

Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007 Feb 1;109(3):536-41

Schmidt M et al. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes--androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res Ther. 2005; 7(5):R938-48.

Schmidt M, Renner C, Loffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998 Sep;158(3):401-7

Schubert M et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 2004 Nov; 89(11):5429-34.

Shores MM et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14; 166(15):1660-5

Sinha-Hikim I et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 2006 Aug; 91(8):3024-33.

Somboonporn W., Davis S., Seif M.W. and Bell R. (2005). Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic Reviews, Issue 4.

Stattin P et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004 Jan 20; 108(3):418-24

Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res. 2006 Jul 20

Tan RS A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003 Mar; 6(1):13-7.

Tilakaratne A, Soory M. Effects of the anti-androgen finasteride on 5 alpha-reduction of androgens in the presence of progesterone in human gingival fibroblasts. J Periodontal Res. 2000 Aug; 35(4):179-85

Travison TG et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2006 Oct 24

Tsujimura A et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male. 2005 Sep-Dec; 8(3-4):175-9

Turhan S et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May; 18(3):159-62.

Turna B et al. Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res. 2004 Dec 09

van den Beld et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men J Clin Endocrinol Metab 2000 Sep;85(9):3276-82

Vermeulen A. Androgens in the aging male. J Clin Endocrinol Metab. 1991. 73:221–224.

Vigna GB et al. Testosterone replacement, cardiovascular system and risk factors in the aging male. J Endocrinol Invest. 2005; 28(11 Suppl Proceedings):69-74

Webb CM et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999 Oct 19; 100(16):1690-6.

Yeap BB et al Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The Health In Men Study. Clin Endocrinol (Oxf). 2008 Mar; 68(3):404-12

Yeap BB et al In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007 May;156(5):585-94

Yeap BB et al Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008 Mar; 65(3):283-9.

Yeap BB et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009 Jul; 94(7):2353-9.

Yeap BB et al. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res. 2009 Jan-Feb; 21(1):24-36.

Yeap BB et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men. The Health In Men Study. Eur JEndocrinol. 2009 Aug 18.

Yeap BB et al. Serum testosterone levels correlate with haemoglobin in middle-aged and older men. Intern Med J. 2008 Aug 16.

Yeap BB et al. Healthier lifestyle predicts higher circulating testosterone in older men: the Health In Men Study. Clin Endocrinol (Oxf). 2009 Mar; 70(3):455-63.

Yeap BB et al. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol. 2008 Jun; 158(6):785-92.

Yeap BB et al. Luteinizing hormone levels are positively correlated with plasma amyloid-beta protein levels in elderly men. J Alzheimers Dis. 2008 Jun; 14(2):201-8.

Yeap BB et al. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab. 2009 Feb; 5(2):113-21.

Zitzmann M Hormone substitution in male hypogonadism Mol Cell Endocrinol 2000 Mar 30; 161(1-2):73-88